This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epizyme Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag2.8%
Nächster Dividendenzahlungsterminn/a
Ex-Dividendendatumn/a
Dividende pro Aktien/a
Gewinn pro Aktie-US$1.23
Erwartete Dividendenrendite in 3 Jahren0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16
Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14
Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10
Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Jun 22

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jun 08
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Jun 02

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25
Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16
Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12
Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Epizyme Q3 2020 Earnings Preview

Nov 05

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Insufficient data to determine if EPZM's dividends per share have been stable in the past.

Wachsende Dividende: Insufficient data to determine if EPZM's dividend payments have been increasing.


Dividendenrendite im Vergleich zum Markt

Epizyme Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von EPZM im Vergleich zum Markt aus?
SegmentDividendenrendite
Unternehmen (EPZM)n/a
Untere 25 % des Marktes (US)1.6%
Markt Top 25 % (US)4.8%
Branchendurchschnitt (Biotechs)2.8%
Analystenprognose in 3 Jahren (EPZM)0%

Bemerkenswerte Dividende: Unable to evaluate EPZM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hohe Dividende: Unable to evaluate EPZM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Barausschüttung an die Aktionäre

Cashflow-Deckung: Unable to calculate sustainability of dividends as EPZM has not reported any payouts.


Entdecken Sie dividendenstarke Unternehmen